Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function
Top Cited Papers
Open Access
- 9 October 2018
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 138 (15), 1537-1550
- https://doi.org/10.1161/circulationaha.118.035901
Abstract
Background: Canagliflozin is approved for glucose lowering in type 2 diabetes and confers cardiovascular and renal benefits. We sought to assess whether it had benefits in people with chronic kidney disease (CKD), including those with an estimated glomerular filtration rate (eGFR) between 30 and 45 mL/min/1.73 m2 in whom the drug is not currently approved for use. Methods: The CANagliflozin cardioVascular Assessment Study Program (CANVAS) randomized 10,142 participants with type 2 diabetes and eGFR greater than 30 mL/min/1.73 m2 to canagliflozin or placebo. The primary outcome was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, with other cardiovascular, renal, and safety outcomes. This secondary analysis describes outcomes in participants with and without CKD, defined as eGFR 2, and according to baseline kidney function (eGFR 2). Results: At baseline, 2039 (20.1%) participants had an eGFR 2, of whom 71.6% had a history of cardiovascular disease. The effect of canagliflozin on the primary outcome was similar in people with CKD (HR 0.70, 95% CI 0.55-0.90) and those with preserved kidney function (HR 0.92, 95% CI 0.79-1.07, P heterogeneity = 0.08). Relative effects on most cardiovascular and renal outcomes were similar across eGFR subgroups, with possible heterogeneity suggested only for the outcome of fatal/nonfatal stroke (P heterogeneity = 0.01), as were results for almost all safety outcomes. Conclusions: The effect of canagliflozin on cardiovascular and renal outcomes was not modified by baseline level of kidney function in people with type 2 diabetes and a history or high risk of cardiovascular disease down to eGFR levels of 30 mL/min/1.73 m2. Reassessing current limitations on the use of canagliflozin in CKD may allow additional individuals to benefit from this therapy. Clinical Trial Registration: URL: https://clinicaltrials.gov. Unique identifiers: NCT01032629, NCT01989754.This publication has 31 references indexed in Scilit:
- Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozinKidney International, 2017
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesThe New England Journal of Medicine, 2017
- Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal FunctionClinical Journal of the American Society of Nephrology, 2017
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes MellitusCirculation, 2016
- Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesThe New England Journal of Medicine, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesThe New England Journal of Medicine, 2015
- Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetesTherapeutic Advances in Endocrinology and Metabolism, 2015
- Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney DiseaseClinical Pharmacokinetics, 2015
- Kidney Disease and Increased Mortality Risk in Type 2 DiabetesJournal of the American Society of Nephrology, 2013
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesThe Lancet, 2010